Expression of PTEN and SHP1, investigated from tissue microarrays in pediatric acute lymphoblastic, leukemia

Pediatric Hematology and Oncology

Volumn 26, Issue 1, 2009, Pages 48-56

  Gauffin, Fredrika ^a   Diffner, Eva ^b   Gustafsson, Bertil ^c   Nordgren, Ann ^a   Wingren, Anette Gjorloff ^d   Sander, Birgitta ^a   Persson, Jenny Liao ^d   Gustafsson, Britt ^a,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Pediatric leukemia; PTEN; SHP1; Tissue microarray

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 1;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW; CANCER DIAGNOSIS; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROL GROUP; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRESCHOOL CHILD; PROTEIN EXPRESSION; SCHOOL CHILD; TISSUE MICROARRAY;

ADOLESCENT; BONE MARROW; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; PTEN PHOSPHOHYDROLASE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 61649117545     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.1080/08880010802625530     Document Type: Article

References (24)

1. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway. Proc Natl Acad Sci U S A. 1999;96:4240-4245.
2. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000;100:387-390.
3. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul Proc. 2006; 46:249-279.
4. White MK, McCubrey JA. Suppression of apoptosis: Role in cell growth and neoplasia. Leukemia. 2001;15:1011-1021.
5. Aggerholm A, Gronbaek K, Guldberg P, Hokland P. Mutational analysis of the tumour suppressor gene MMAC1/PTEN in malignant myeloid disorders. Euro J Haematol. 2000;65:109-113.
6. Bedolla R, Prihoda TJ, Kreisberg JI, et al. Determining risk of biochemical recurrence in prostate cancer by immunohistochemical detection of PTEN expression end Akt activation. Clin Cancer Res. 2007;13:3860-3867.
7. Dahia PLM, Aguiar RCT, Alberta J, et al. PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet. 1999;8:185-193.
8. Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999;155:1253-1260.
9. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, et al. Promoter hypermethylation of cancer-related genes: A strong independent prognostic factor in acute lymphoblastic leukemia. Blood. 2004;104:2492-2498.
10. Stahl JM, Cheung M, Sharma A, Trivedi NR, Shanmugam S, Robertson GP. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res. 2003;63:2881-2890.
11. Yang L, Kuang LG, Zheng HC, et al. PTEN encoding product: A marker for tumorigenesis and progression of gastric carcinoma. World J Gastroenterol 2003;9:35-39.
12. Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: Diversified control of cell growth, inflammation, and injury. Histol Histopathol. 2007;22: 1251-1267.
13. Roskoski R. Signaling by Kit protein-tyrosine kinase: The stem cell factor receptor. Biochem Biophys Res Commun. 2005;337:1-13.
14. Wu CY, Sun MZ, Liu LJ, Zhou GW. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene. 2003;306:1-12.
15. Koyama M, Oka T, Ouchida M, et al. Activated proliferation of B-cell lymphomas/leukemias with the SHP1 gene silencing by aberrant CpG methylation. Lab Invest. 2003;83;1849-1858.
16. Oka T, Ouchida M, Koyama M, et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 2002;62:6390-6394.
17. Reddy J, Shivapurkar N, Takahashi T, et al. Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene. 2005;24:732-736
18. Gustafsson G, Langmark F, Pihkala U, Heyman M, de Verdier B, Lilleaas I. Childhood Cancer in the Nordic Countries. Gothenburg, Sweden: Nordic Society of Pediatric Haematology and Oncology;1999: 83-152.
19. Fridberg M, Servin A, Anagnostaki L, et al. Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: Higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leuk Lymphoma. 2007;48: 2221-2232.
20. Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukemia-initiating cells. Nature. 2006;441:475-482.
21. Avellino R, Romano S, Parasole R, et al. Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells. Blood, 2005; 106:1400-1406.
22. Yang J, Liu J, Zheng J, et al. A reappraisal by quantitative flow cytometry analysis of PTEN expression in acute leukemia. Leukemia. 2007;21:2072-2074.
23. Mena-Duran AV, Togo SH, Bazhenova L, et al. SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: A new prognostic factor. Br J Haematol. 2005;129:791-794.
24. Amin HM, Hoshino K, Yang H, Lin Q, La R, Garcia-Manero G. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-I (ShpI) is associated with progression of chronic myeloid leukemia. J Pathol. 2007;212:402-410.